NYXH
Nyxoah
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 1
consensus rating "Strong Buy"
Revenue Beats Expectation
EPS Beats Expectation
Bearish Abandoned Baby
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About NYXH
Nyxoah Sa
A Belgian supplier of sleep apnea devices
Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium
--
Nyxoah SA was incorporated indefinitely in Belgium on July 15, 2009. The company is a medical technology company focused on the development and commercialization of innovative solutions for the treatment of obstructive sleep apnea (OSA). The company-led solution is the Genio System, a CE-marked, patient-centered, minimally invasive, next-generation hypoglossal nerve stimulation or HGNS therapy for the treatment of moderate to severe OSA. OSA is the most common sleep-disordered breathing disorder in the world and is associated with an increased risk of death and co-morbidities including cardiovascular disease, depression and stroke. The company's innovative technology platform is the first-of-its-kind HGNS device, designed to treat OSA through bilateral stimulation and achieve peaceful night sleep by keeping an open airway.
Company Financials
EPS
NYXH has released its 2024 Q1 earnings. EPS was reported at -0.45, versus the expected -0.42, missing expectations. The chart below visualizes how NYXH has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NYXH has released its 2024 Q4 earnings report, with revenue of 1.31M, reflecting a YoY change of -35.21%, and net profit of -17.75M, showing a YoY change of -47.31%. The Sankey diagram below clearly presents NYXH’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
